Abstract
The past 25 years have witnessed an explosion of investigative attempts to identify clinically useful biomarkers which can have meaningful impacts for patients with urologic cancers. However, in spite of the enormous amount of research aiming to identify markers with the hope of impacting patient care, only a handful have proven to have true clinical utility. Improvements in targeted imaging, pan-omics evaluation, and genetic sequencing at the tissue and single-cell levels have yielded many potential targets for continued biomarker investigation. This article, as one in this series for the 25th Anniversary Issue of Urologic Oncology: Seminars and Original Investigations, serves to give a perspective on our progress and failures over the past quarter-century in our highest volume urologic cancers: prostate, bladder, and kidney cancers.
Original language | English (US) |
---|---|
Pages (from-to) | 602-617 |
Number of pages | 16 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 39 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2021 |
Keywords
- Biomarker
- Bladder
- Cancer
- Genomics
- Kidney
- Prostate
ASJC Scopus subject areas
- Oncology
- Urology